title: Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor.
abstract: Toxicity has been observed in mice receiving recombinant human tumor necrosis factor (rhTNF). In the present experiments, several chemicals were used to determine whether they could prevent the lethality of rhTNF without impairing its antitumor activity. Injection of phospholipase A2, cyclooxygenase, and lipoxygenase inhibitors at the same time as rhTNF administration could prevent the lethality of rhTNF, but the antitumor activity was also reduced. Urinastatin and reduced glutathione could prevent the lethality while reducing the activity. In contrast, by pretreatment with O2 scavengers, the lethality of rhTNF was markedly reduced without impairment of the antitumor activity of rhTNF. Antihistamines exerted no influence on the lethality of rhTNF. Histopathologic examinations have demonstrated that the capillaries of the tumor tissue show aggregation of platelets and formation of fibrin adherent to the vascular surface after TNF administration. Heparin or protamine revealed no effects against the lethality of rhTNF. These results strongly suggest that the arachidonic cascade is deeply related to the antitumor activity of TNF and its side effects. Pretreatment with O2 scavengers, especially bismuth subnitrate, could prevent the lethality of rhTNF without impairing its antitumor activity.
authors: Department of Internal Medicine, University of Tokyo, Japan.
authors: N
authors: N
authors: Satomi
authors: A
authors: A
authors: Sakurai
authors: R
authors: R
authors: Haranaka
authors: K
authors: K
authors: Haranaka
mesh_terms: D000818:Animals; D001769:Blood; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy*; D002746:Chlorpromazine / Q000494:pharmacology; D003348:Cortisone / Q000494:pharmacology; D004359:Drug Therapy, Combination; D005260:Female; D005978:Glutathione / Q000494:pharmacology; D051379:Mice; D008807:Mice, Inbred BALB C; D009026:Mortality; D009364:Neoplasm Recurrence, Local; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D014810:Vitamin E / Q000494:pharmacology
chemical_list: D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014810:Vitamin E; D005978:Glutathione; D002746:Chlorpromazine; D003348:Cortisone